
    
      This is a single-center, prospective, single arm study to evaluate feasibility of UroNAV
      Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined
      prostate cancer. All subjects will be treated and then followed up clinically for up to 24
      months to evaluate any procedure or device related adverse events as well as to assess
      efficacy endpoints of the study. Additional data related to quality of life of treated
      subjects will also be collected
    
  